login | register | order now | view cart | feedback
cDNA Synthesis & Library Construction

Products >  cDNA_Synthesis_and_Library_Construction >  NGS_Learning_Resources >  CF_Nucleic_Acid_Sequencing

Tech Note: Ligation-Free ChIP-Seq Library Preparation

Cell-free Nucleic Acid Sequencing

Faster time to better results from cell-free nucleic acids

Speed up the development of your liquid biopsy assays

SMARTer ThruPLEX Plasma-seq Kit for cell-free DNA (cfDNA)

When it comes to assay development, a streamlined protocol means faster results, a need for less starting material, and less hands-on time—leading to lower variability between samples, runs, and operators, and therefore more reproducible and reliable results.

The SMARTer ThruPLEX Plasma-seq kit is developed and optimized for cell-free DNA. Its innovative chemistry offers many advantages:

  • Single-tube workflow—no transfers or purification step required
  • Ultra-fast protocol—three steps, two hours to complete
  • Optimized reagents—no titration of adapter concentration
  • Superior performance—high-complexity NGS libraries and reproducible results

  • BCR development

    Figure 1. Fewer steps and pipetting operations translate to highest sensitivity and reproducibility. The SMARTer ThruPLEX Plasma-seq kit provided the most reproducible and unbiased GC coverage across the human genome, showing minimal variability across the nine plasma samples tested. Libraries were prepared from cell-free DNA isolated from an equivalent of 1 ml of plasma sample and sequenced on an Illumina NextSeq® 500. Four separate plasma samples were used to construct the NEBNext Ultra libraries.

    SMARTer ThruPLEX technology's high performance has enabled scientists to address challenges in obtaining insights from cell-free DNA samples, advancing the frontier of liquid biopsies to demonstrate clinical utility. Kitzman et al. prepared NGS libraries from cfDNA extracted from maternal plasma samples using a SMARTer ThruPLEX Plasma-seq kit to demonstrate, for the first time, the noninvasive determination of a fetal genome sequence. Murtaza et al. used a SMARTer ThruPLEX Plasma-seq kit to perform whole exome analysis on ctDNA to monitor patients’ tumor evolution before and after treatment, demonstrating the first use of NGS to noninvasively identify mutations by sequencing the cfDNA from patients.

    Recently, researchers from the Medical College of Wisconsin and the Mayo Clinic used SMARTer ThruPLEX technology to identify cfDNA biomarkers for prostate, lung, and colon cancer. Watch the webinar here.

    SMARTer Stranded Total RNA-Seq Kit v2 for cell-free RNA (cfRNA)

    For sensitive detection of transcripts from Illumina-ready stranded NGS libraries generated from cell-free RNA, we offer the SMARTer Stranded Total RNA-seq Kit v2 - Pico Input Mammalian kit (Pico v2). This kit features a highly streamlined workflow that can be completed in 6 hours to generate high-quality, stranded NGS libraries from 250 pg to 10 ng of purified total RNA, isolated from cell-free RNA derived from plasma and other biofluids. The data shown below demonstrates the sensitivity of the kit in detecting transcripts from as little as 150 pg of input, in comparison to the ideal recommended input amount of 1 ng.

    Read our tech note to learn more.

    BCR development

    Figure 2. Sensitive detection of transcripts at picogram input of cell-free RNA with Pico v2 kit. While the ideal input of cfRNA for SMARTer Stranded Total RNA-seq Kit starts at 1 ng, the kit is sensitive enough to generate good quality NGS libraries from lower amounts of cfRNA. The data here shows the performance metrics generated using the Pico v1 kit compared to the Pico v2 kit using input amounts of 150 pg and 1 ng. The Pico v2 kit provided improved performance, yielding a low percentage of ribosomal and mitochondrial reads and a high number of genes detected.


    • Kitzman, J. O. et al. Noninvasive Whole-Genome Sequencing of a Human Fetus. Sci. Transl. Med. 4, 137ra76 (2012).
    • Murtaza, al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.Nature 497, 108–112 (2013).

    Download PDF >>

    Top of page

    Takara Bio USA is a Takara Bio Company © 2018 Privacy Policy | Terms & Conditions | Terms of Use